Answers are grounded in this paper and cite their sources.
This commentary refers to ‘The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials’, by N.H. Adamstein et al., doi:10.1093/eurheartj/ehaa1034 and the discussion piece ‘Neutrophil–lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis’, by N. Zhang et al., doi:10.1093/eurheartj/ehab158. We thank the authors for their thought-provoking commentary on our original article.1 , 2 The authors raise an important question: what is the clinical utility of the neutrophil–lymphocyte ratio (NLR) in patients with immune checkpoint inhibitor (ICI)-associated atherosclerosis? This question introduces a broader topic of interest: what is the clinical utility of the NLR in patients with cardiovascular disease and systematically abnormal NLR? Since the NLR is a ratio between two absolute cell counts, any physiological state that differentially alters either neutrophils or lymphocytes will systematically alter the NLR. Such states include acute inflammation, hematological malignancies, immune deficiencies and immunomodulatory medication use. For example, the median NLR in a study on acute coronary syndrome was 3.56,3 whereas the NLR in the apparently healthy participants of JUPITER was 2.10.2 ICIs target CTLA-4 or PD-1/PD-L1, which dampen the CD8 T-cell response under normal conditions. In this way, ICIs have unique effects on circulating T-cell populations, and possibly the NLR by extension. Given these effects, and the inherent complexity of interpreting changes in a ratio biomarker, it becomes challenging to speculate on generalizing our findings from stable CAD to patients with both cancer and on ICIs. While our analysis excluded patients with autoinflammatory, autoimmune, or neoplastic diseases (including those on ICIs), the NLR may be useful in such populations. Indeed, the NLR has been heavily studied in the setting of most solid tumours4 and has been evaluated as a tool for predicting response to ICI therapy.5 However, there are additional considerations when applying the NLR for risk prediction in these populations. First, the NLR’s distribution needs to be defined for each population. Patients on ICIs may have a vastly different ‘normal’ range of NLRs compared to patients with stable CAD. Therefore, while an NLR of 3.5 was associated with CV events and mortality in CANTOS, the relevant cut-point may differ in patients receiving ICIs. Second, the NLR needs to remain stable over time to function as a useful biomarker. In the case of ICIs, it is possible that the NLR is deranged during treatment and then normalizes once treatment is complete, requiring adjustment of clinical cut-points as a patient progresses through each cycle. Finally, if the NLR is found to be predictive of CV risk in patients with ICI-associated atherosclerosis, it is unknown whether this association would reflect true pathophysiological interactions unique to ICIs or if it would be predictive for the same reasons as in the general population. The NLR has been shown to be an effective predictor of cardiovascular risk in both primary and secondary prevention settings.2 It is still unknown whether the associations are causal, but its independence from hsCRP generates many hypotheses about the complex interactions between the immune system and atherothrombosis. As we learn to harness the power of the immune system, understanding these key interactions and applying them to risk prediction and therapeutic intervention will become even more important. To this end, future trials on ICIs should pre-specify measurement of the NLR at entry and follow-up. Conflict of interest: N.H.A. has no conflicts of interest to disclose. P.M.R. served as the Principal Investigator for the CANTOS, CIRT, JUPITER, SPIRE-1, and SPIRE-2 trials, which were supported by investigator-initiated research grants to the Brigham and Women’s Hospital by Novartis, the National Heart Lung and Blood Institute, AztraZeneca, and Pfizer, respectively. P.M.R. has served as a consultant to Novartis, Inflazome, Flame, Agepha, Uppton, and Corvidia and was listed as a co-inventor on patents related to inflammatory biomarkers in cardiovascular disease that, now expired, were licenced in the past to Siemens and AstraZeneca.
No takes yet. Share an insight, caveat, or question.
Adamstein et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: